Loading
A phase 2 trial of Docetaxel in advanced solid tumours, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., active and no longer recruiting.
SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors is a phase 2 interventional study registered as NCT05631262 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 321 participants enrolled, started 2022-11-30 and due to reach its primary completion in 2026-12-30. Interventions recorded: SKB264 and Docetaxel.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Docetaxel, Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.